Avacta Affi News Today

Investegate announcements from Abingdon Health PLC, Trading and Strategic Update

Britain’s Avacta Group has halted sales of its COVID-19 lateral flow test in order to replace the antibody in the device and ensure its effectiveness.

Investegate announcements from Abingdon Health PLC, Update on AffiDX� SARS-CoV-2 antigen LFT

Investegate announcements from Avacta Group PLC, MHRA Confirms Registration of Lateral Flow Test

Submitting... Avacta said a Declaration of Conformity for CE mark of its AffiDX SARS-CoV-2 antigen rapid test for professional use has been submitted to the Medicines and Healthcare products Regulatory Agency (MHRA). The group has developed a SARS-CoV-2 antigen lateral flow test using its Affimer platform to detect the coronavirus spike antigen. Affimers are Avacta’s high-tech alternative to antibodies. Avacta recently announced data from a clinical study on 98 positive Covid-19 samples that ...

A partnership which will accelerate Avacta’s AffiDX™ SARS-CoV-2 lateral flow rapid antigen test to market is enabling the test to be CE marked for professional use under Mologic’s existing ISO13485 quality system. Click to read more...